NCT01474122View on ClinicalTrials.gov

Macitentan for the Treatment of Digital Ulcers in Systemic Sclerosis Patients

PHASE3TerminatedINTERVENTIONAL
Enrollment

265

Participants

Timeline

Start Date

December 31, 2011

Primary Completion Date

February 28, 2014

Study Completion Date

February 28, 2014

Conditions
Digital Ulcers
Interventions
DRUG

Macitentan 3 mg

Macitentan 3-mg tablet once daily

DRUG

Macitentan 10 mg

Macitentan 10-mg tablet once daily

DRUG

Placebo

Placebo tablet matching macitentan tablet, once daily

Sponsors

Lead Sponsor

Actelion
All Listed Sponsors
lead

Actelion

INDUSTRY

NCT01474122 - Macitentan for the Treatment of Digital Ulcers in Systemic Sclerosis Patients | Biotech Hunter | Biotech Hunter